- 3
- 1
LIONEL PERRIER
4
Documents
Présentation
Publications
- 3
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 2
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 1
- 4
- 3
- 1
- 1
- 1
- 1
- 1
- 1
Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myelomaApplied Health Economics and Health Policy, 2013, 11 (2), pp. 129-138. ⟨10.1007/s40258-013-0011-7⟩
Article dans une revue
halshs-00752571v1
|
|
|
|
Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.BMC Health Services Research, 2012, 12 (1), pp.82. ⟨10.1186/1472-6963-12-82⟩
Article dans une revue
inserm-00711845v1
|
A cost-effectiveness analysis of the ZIRA test in breast cancer21th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, May 2016, Washington, United States
Communication dans un congrès
halshs-01366993v1
|
|
Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), Baltimore, Etats-Unis, 25 mai 2011, May 2011, Baltimore, United States
Communication dans un congrès
halshs-00628829v1
|